Antibody Response 3 Months after 2-Dose SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease

Evangelos Tsipotis; Sarah Frey; Caoilfhionn Connolly; William A. Werbel; Reezwana Chowdhury; Sharon Dudley-Brown; Joanna M. Melia; Alyssa M. Parian; Brindusa Truta; Huimin Yu; Florin M. Selaru; Dorry L. Segev; Mark Lazarev

doi:10.14309/ajg.0000000000001668

Antibody Response 3 Months after 2-Dose SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease

Evangelos Tsipotis, Sarah Frey, Caoilfhionn Connolly, William A. Werbel, Reezwana Chowdhury, Sharon Dudley-Brown, Joanna M. Melia, Alyssa M. Parian, Brindusa Truta, Huimin Yu, Florin M. Selaru, Dorry L. Segev, Mark Lazarev

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

INTRODUCTION:The response to SARS-CoV-2 vaccination of patients with inflammatory bowel disease (IBD) on immune-modifying therapies requires further investigation because previous studies indicate that patients on immune therapy might have decreased antibody concentrations.METHODS:We present the antireceptor binding domain antibody response over a period of 3 months in 217 patients with IBD who completed standard 2-dose SARS-CoV-2 mRNA vaccine series.RESULTS:Almost all (98.6%) IBD vaccine recipients had a positive antireceptor binding domain antibody response at least 3 months after vaccination. Decreased antibody titers at 3 months were seen in a subset of patients on antitumor necrosis factor-alpha. Approximately 10% of the participants with high-titer antibodies at 1 month had a decrease to low-positive titers at 3 months, which was mostly observed in those on combination therapy and antitumor necrosis factor-alpha monotherapy.DISCUSSION:Larger longitudinal studies are required to define the response in IBD population and its clinical impact.

Original language	English (US)
Pages (from-to)	798-801
Number of pages	4
Journal	American Journal of Gastroenterology
Volume	117
Issue number	5
DOIs	https://doi.org/10.14309/ajg.0000000000001668
State	Published - May 1 2022

ASJC Scopus subject areas

Gastroenterology
Hepatology

Access to Document

10.14309/ajg.0000000000001668

Cite this

Tsipotis, E., Frey, S., Connolly, C., Werbel, W. A., Chowdhury, R., Dudley-Brown, S., Melia, J. M., Parian, A. M., Truta, B., Yu, H., Selaru, F. M., Segev, D. L., & Lazarev, M. (2022). Antibody Response 3 Months after 2-Dose SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease. American Journal of Gastroenterology, 117(5), 798-801. https://doi.org/10.14309/ajg.0000000000001668

Tsipotis, E, Frey, S, Connolly, C, Werbel, WA , Chowdhury, R, Dudley-Brown, S, Melia, JM , Parian, AM, Truta, B, Yu, H , Selaru, FM, Segev, DL & Lazarev, M 2022, 'Antibody Response 3 Months after 2-Dose SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease', American Journal of Gastroenterology, vol. 117, no. 5, pp. 798-801. https://doi.org/10.14309/ajg.0000000000001668

@article{bf4ed656a63346249254ca28eac7b777,

title = "Antibody Response 3 Months after 2-Dose SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease",

abstract = "INTRODUCTION:The response to SARS-CoV-2 vaccination of patients with inflammatory bowel disease (IBD) on immune-modifying therapies requires further investigation because previous studies indicate that patients on immune therapy might have decreased antibody concentrations.METHODS:We present the antireceptor binding domain antibody response over a period of 3 months in 217 patients with IBD who completed standard 2-dose SARS-CoV-2 mRNA vaccine series.RESULTS:Almost all (98.6%) IBD vaccine recipients had a positive antireceptor binding domain antibody response at least 3 months after vaccination. Decreased antibody titers at 3 months were seen in a subset of patients on antitumor necrosis factor-alpha. Approximately 10% of the participants with high-titer antibodies at 1 month had a decrease to low-positive titers at 3 months, which was mostly observed in those on combination therapy and antitumor necrosis factor-alpha monotherapy.DISCUSSION:Larger longitudinal studies are required to define the response in IBD population and its clinical impact.",

author = "Evangelos Tsipotis and Sarah Frey and Caoilfhionn Connolly and Werbel, {William A.} and Reezwana Chowdhury and Sharon Dudley-Brown and Melia, {Joanna M.} and Parian, {Alyssa M.} and Brindusa Truta and Huimin Yu and Selaru, {Florin M.} and Segev, {Dorry L.} and Mark Lazarev",

year = "2022",

month = may,

day = "1",

doi = "10.14309/ajg.0000000000001668",

language = "English (US)",

volume = "117",

pages = "798--801",

journal = "American Journal of Gastroenterology",

issn = "0002-9270",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Antibody Response 3 Months after 2-Dose SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease

AU - Tsipotis, Evangelos

AU - Frey, Sarah

AU - Connolly, Caoilfhionn

AU - Werbel, William A.

AU - Chowdhury, Reezwana

AU - Dudley-Brown, Sharon

AU - Melia, Joanna M.

AU - Parian, Alyssa M.

AU - Truta, Brindusa

AU - Yu, Huimin

AU - Selaru, Florin M.

AU - Segev, Dorry L.

AU - Lazarev, Mark

PY - 2022/5/1

Y1 - 2022/5/1

N2 - INTRODUCTION:The response to SARS-CoV-2 vaccination of patients with inflammatory bowel disease (IBD) on immune-modifying therapies requires further investigation because previous studies indicate that patients on immune therapy might have decreased antibody concentrations.METHODS:We present the antireceptor binding domain antibody response over a period of 3 months in 217 patients with IBD who completed standard 2-dose SARS-CoV-2 mRNA vaccine series.RESULTS:Almost all (98.6%) IBD vaccine recipients had a positive antireceptor binding domain antibody response at least 3 months after vaccination. Decreased antibody titers at 3 months were seen in a subset of patients on antitumor necrosis factor-alpha. Approximately 10% of the participants with high-titer antibodies at 1 month had a decrease to low-positive titers at 3 months, which was mostly observed in those on combination therapy and antitumor necrosis factor-alpha monotherapy.DISCUSSION:Larger longitudinal studies are required to define the response in IBD population and its clinical impact.

AB - INTRODUCTION:The response to SARS-CoV-2 vaccination of patients with inflammatory bowel disease (IBD) on immune-modifying therapies requires further investigation because previous studies indicate that patients on immune therapy might have decreased antibody concentrations.METHODS:We present the antireceptor binding domain antibody response over a period of 3 months in 217 patients with IBD who completed standard 2-dose SARS-CoV-2 mRNA vaccine series.RESULTS:Almost all (98.6%) IBD vaccine recipients had a positive antireceptor binding domain antibody response at least 3 months after vaccination. Decreased antibody titers at 3 months were seen in a subset of patients on antitumor necrosis factor-alpha. Approximately 10% of the participants with high-titer antibodies at 1 month had a decrease to low-positive titers at 3 months, which was mostly observed in those on combination therapy and antitumor necrosis factor-alpha monotherapy.DISCUSSION:Larger longitudinal studies are required to define the response in IBD population and its clinical impact.

UR - http://www.scopus.com/inward/record.url?scp=85129997031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85129997031&partnerID=8YFLogxK

U2 - 10.14309/ajg.0000000000001668

DO - 10.14309/ajg.0000000000001668

M3 - Article

C2 - 35103023

AN - SCOPUS:85129997031

SN - 0002-9270

VL - 117

SP - 798

EP - 801

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

IS - 5

ER -

Antibody Response 3 Months after 2-Dose SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this